What is the strategic rationale behind Pfizer's acquisition of Medivation?

The primary strategic rationale is to significantly enhance Pfizer's oncology business. Medivation's lead product, Xtandi, is a highly successful drug for treating prostate cancer, and its addition is expected to complement Pfizer's existing oncology portfolio and drive future growth in this key therapeutic area.

How will the acquisition be financed, and what is the expected timeline?

Pfizer anticipates financing the acquisition through its existing cash reserves. The transaction is expected to close in the third or fourth quarter of 2016, subject to customary closing conditions, including regulatory approvals and the successful completion of the tender offer.

What happens to Medivation's outstanding equity awards (options, RSUs, etc.)?

Upon the effective time of the merger, all outstanding Medivation stock options, stock appreciation rights, and restricted stock units will become fully vested and will be cancelled in exchange for a cash payment equal to the offer price ($81.50) per share, less any applicable exercise price for options, or directly the offer price for RSUs and SARs. Shares purchased under Medivation's Employee Stock Purchase Plan will also be converted into the right to receive the offer price in cash.

Are there any conditions that could prevent the deal from closing?

Yes, the tender offer is subject to customary closing conditions, including that a majority of Medivation's outstanding shares are tendered and not withdrawn. Additionally, regulatory approvals, such as the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and the absence of any injunctions prohibiting the transaction are required. The transaction is not subject to a financing condition.

PFE 8-K: Material Agreements

Summary

Pfizer Inc. has announced its definitive agreement to acquire Medivation, Inc. through a cash tender offer for $81.50 per share, valuing the transaction at approximately $14 billion. This strategic move aims to bolster Pfizer's oncology portfolio, particularly with Medivation's blockbuster prostate cancer drug, Xtandi. The acquisition, structured as a tender offer followed by a merger, is expected to be financed by existing cash and is anticipated to close in the third or fourth quarter of 2016. The deal includes customary closing conditions and regulatory approvals, with a "no-shop" provision in the merger agreement, subject to a fiduciary out clause and a termination fee of $510 million payable by Medivation under specific circumstances.

Key Highlights

1Pfizer to acquire Medivation for $81.50 per share in cash via a tender offer.
2Total transaction value is approximately $14 billion.
3The acquisition significantly strengthens Pfizer's oncology pipeline, notably with the addition of Xtandi (enzalutamide).
4Transaction is expected to be financed by Pfizer's existing cash resources.
5The deal is structured as a tender offer followed by a merger, with expected closing in Q3 or Q4 2016.
6Customary closing conditions, including regulatory approvals, apply.
7Medivation's stock options, SARs, and RSUs will be cashed out at closing.

PFIZER INC 8-K Report, Material Agreement (Aug 22, 2016)

Summary

Key Highlights

Frequently Asked Questions